**ESOPH-F 3 of 13**

External Request: Consider revising the trastuzumab caveats for first-line therapy of HER2 overexpressing metastatic adenocarcinoma by removing the statement “Combination with other chemotherapy agents (category 2B)”.  

Based on a review of data and discussion, the panel consensus supported revising the sub-bullets for the recommendation “Trastuzumab should be added to first-line chemotherapy for HER2 overexpressing metastatic adenocarcinoma” as follows:  
- Combination with fluoropyrimidine and cisplatin (category 1)  
- Combination with other chemotherapy agents (category 2B)  
- Combination with fluoropyrimidine and platinum (category 1 in combination with cisplatin; category 2A in combination with other platinum agents)  
- Trastuzumab is not recommended for use with anthracyclines

**ESOPH-F 4 of 13**

Internal Request
Institutional review suggestion to add pembrolizumab to the “preferred” category for third-line or beyond PD-L1 positive (CPS≥1) EGJ adenocarcinoma rather than “other recommended regimens”.  

Based on a review of the data and discussion, the panel consensus supported moving the pembrolizumab recommendation “For third-line or subsequent therapy for esophageal and EGJ adenocarcinoma with PD-L1 expression levels by CPS of ≥1” from “Other Recommended Regimens” to “Preferred Regimens”.

| Guideline Page and Request | Panel Discussion/References | Vote |  |  |  |  |
|---------------------------|----------------------------|------|---|---|---|
| **ESOPH-F 3 of 13**       | Based on a review of data and discussion, the panel consensus supported revising the sub-bullets for the recommendation “Trastuzumab should be added to first-line chemotherapy for HER2 overexpressing metastatic adenocarcinoma” as follows:  
- Combination with fluoropyrimidine and cisplatin (category 1)  
- Combination with other chemotherapy agents (category 2B)  
- Combination with fluoropyrimidine and platinum (category 1 in combination with cisplatin; category 2A in combination with other platinum agents)  
- Trastuzumab is not recommended for use with anthracyclines | 24 | 0 | 0 | 4 |
| **ESOPH-F 4 of 13**       | Based on a review of the data and discussion, the panel consensus supported moving the pembrolizumab recommendation “For third-line or subsequent therapy for esophageal and EGJ adenocarcinoma with PD-L1 expression levels by CPS of ≥1” from “Other Recommended Regimens” to “Preferred Regimens”. | 24 | 0 | 0 | 4 |